Objective The aim of the study was to observe the influence of autologous cytokine-induced killer cell （CIK） treatment on the objective efficacy and safety of gefitinib in advanced non-small ceil lung cancer （NSCLC...Objective The aim of the study was to observe the influence of autologous cytokine-induced killer cell （CIK） treatment on the objective efficacy and safety of gefitinib in advanced non-small ceil lung cancer （NSCLC）. Methods Sixty-six patients with NSCLC received gefitinib as second-line treatment. They were randomly divided into 2 groups, and informed consent forms were signed before grouping. Gefitinib was administrated to the control group, and autologous CIK treatment was added to the observation group. The objective treatment and adverse reactions were evaluated in both groups. Results The objective response rate （ORR） and the disease control rate （DCR） of the observation group were slightly higher than those of the control group, although no statistical differences were found between the 2 groups （P 〉 0.05）. The incidences of diarrhea, fatigue, anorexia, oral ulcers, and myelosuppression in the observation group were much lower than those in the control group （P 〈 0.05）. However, there were no statistical differences between the incidences of skin rash, and liver and kidney toxicities （P 〉 0.05）. Conclusion Autologous CIK in combination with gefitinib is effective as second-line treatment fore ad- vanced NSCLC, and can significantly reduce adverse reactions and improve the objective efficacy.展开更多
Objective: To detect the expression of CEA mRNA in patients with non-small cell lung cancer (NSCLC) and to investigate it's significance. Methods: The blood samples were taken from peripheral veins of 70 patients ...Objective: To detect the expression of CEA mRNA in patients with non-small cell lung cancer (NSCLC) and to investigate it's significance. Methods: The blood samples were taken from peripheral veins of 70 patients with NSCLC and 18 patients with benign diseases at 3 intervals during the surgery. The transcription of carcinoembryonic antigen messenger ribonucleic acid (CEA mRNA) was assayed by means of nested reverse transcriptase polymerase chain reaction (RT-PCR) and micro-fluid chip. Results: The CEA mRNA positive rates at each of the 3 time spots were as follows: 50% at beginning of the surgery (group 1), 62.8% in the samples collected when ligating the pulmonary vein (group 2) and 57.1% in samples collected 1 h after ligation (group 3). A significant difference was found between groups 1 and 2 (χ2 = 7.114, P < 0.05). Con-clusion: Cancer cell dissemination during surgery is demonstrated indirectly in our study, when to ligate the pulmonary vein (earlier or later) may affect the quantity of tumor cells spread into the circulation.展开更多
Objective:To study the correlation of peripheral blood NK cell content with tumor marker content and proliferation molecule expression in patients with non-small cell lung cancer (NSCLC).Methods: A total of 80 patient...Objective:To study the correlation of peripheral blood NK cell content with tumor marker content and proliferation molecule expression in patients with non-small cell lung cancer (NSCLC).Methods: A total of 80 patients who were diagnosed with NSCLC in our hospital between June 2014 and October 2016 were selected as the NSCLC group of the research, and 96 healthy volunteers who received physical examination in our hospital during the same period were selected as the control group of the research. The peripheral blood NK cell content and serum tumor marker contents of two groups of subjects were determined, and the proliferation molecule expression levels in lung cancer focus tissue and focus tissue adjacent to carcinoma of NSCLC group were determined.Results:Peripheral blood NK cell content of NSCLC group was significantly lower than that of control group;serum CEA, CA125, Cyfra21-1 and HE4 contents were significantly higher than those of control group, and serum CEA, CA125, Cyfra21-1 and HE4 contents of NSCLC patients with high NK cell content were significantly lower than those of NSCLC patients with low NK cell content;c-myc, c-FLIP, Livin, Moesin and k-ras protein expression in lung cancer focus tissue were significantly higher than those in focus tissue adjacent to carcinoma, and c-myc, c-FLIP, Livin, Moesin and k-ras protein expression in lung cancer focus tissue with high NK cell content were significantly lower than those in lung cancer focus tissue with low NK cell content.Conclusion: Peripheral blood NK cell content significantly reduces in patients with NSCLC and is associated with the cancer cell proliferation activity.展开更多
Background: Lung cancer is among the most common cancers. Search is ongoing to find biomarkers to improve the diagnosis lung cancer techniques in early stages. In this study we evaluate the sensitivity and specificity...Background: Lung cancer is among the most common cancers. Search is ongoing to find biomarkers to improve the diagnosis lung cancer techniques in early stages. In this study we evaluate the sensitivity and specificity of the MUC1 and CEA gene expressions in the peripheral blood of non-small cell lung cancer (NSCLC). Material and Methods: This study was done in Masih Daneshvari Hospital, Tehran, Iran and was case/control study that conducted on 30 NSCLC patients and 30 healthy controls. Peripheral blood was collected and total RNA was extracted then cDNA was synthesized. Sample was separately assessed by real time PCR. Results: The expression of CEA gen was positive in 24 patients indicating 80% sensitivity for this marker. The expression of CEA gen was positive in 9 controls out of 30 each. A statistically significant difference was detected between patients and healthy controls with regard to CEA mRNA expression (P 0.001). The MUC1 gen expressed in 20 out of 30 patients, while it expressed in 3 controls. The difference in MUC1 mRNA expression was statistically significant between NSCLC patients and healthy controls (P 0.001). Conclusion: MUC1 and CEA are molecular biomarkers with relatively favorable sensitivity for primary diagnosis of NSCLC.展开更多
目的观察非小细胞肺癌患者癌胚抗原(CEA)、血清细胞角蛋白19片段(CYFRA21-1)、糖类抗原125(CA125)水平在治疗前后的变化,探讨3项肿瘤标志物在评价非小细胞肺癌患者近期疗效和预后中的应用价值。方法选取80例晚期(Ⅲ期、Ⅳ期)非小细胞肺...目的观察非小细胞肺癌患者癌胚抗原(CEA)、血清细胞角蛋白19片段(CYFRA21-1)、糖类抗原125(CA125)水平在治疗前后的变化,探讨3项肿瘤标志物在评价非小细胞肺癌患者近期疗效和预后中的应用价值。方法选取80例晚期(Ⅲ期、Ⅳ期)非小细胞肺癌患者,均接受至少2个周期的顺铂+吉西他滨(GP)方案或紫杉醇+顺铂(PC)方案化疗。所有患者在化疗前后均检测其血清CEA、CYFRA21-1、CA125水平。结果腺癌患者CEA及CA125水平比鳞癌更高,而鳞癌CYFRA21-1水平比腺癌更高(P<0.05);Ⅳ期、外转移部位数量≥3的患者的CEA、CYFRA21-1、CA125水平均比Ⅲ期、外转移部位数量<3的患者高(P<0.05)。PR患者治疗后血清CEA、CYFRA21-1、CA125水平均比治疗前显著降低(P<0.05)。SD患者治疗前后3项肿瘤标志物水平差异不明显(P>0.05)。PD患者治疗后血清CEA、CYFRA21-1、CA125水平均显著增加(P<0.05)。CEA<15 ng/m L患者的平均PFS、OS均比CEA≥15 ng/m L的患者长(8.48±3.24 VS 5.04±2.03;17.11±5.13 VS 13.11±4.12);CYFRA21-1<5 ng/m L患者的平均PFS、OS均比CYFRA21-1≥5 ng/m L的患者长(8.92±3.47 VS 4.88±2.31;18.01±5.80 VS 13.44±4.75);CA125<30 U/m L患者的平均PFS、OS均比CA125≥30 U/m L的患者长(7.96±3.51 VS 5.91±2.75;16.47±6.52 VS 13.51±5.18),差异均有统计学意义(P<0.05)。结论血清CEA、CYFRA21-1、CA125水平对肿瘤分期及病理分型具有一定的参考意义,在评价晚期非小细胞肺癌患者的近期疗效和预后水平中具有较好的应用价值。展开更多
文摘Objective The aim of the study was to observe the influence of autologous cytokine-induced killer cell （CIK） treatment on the objective efficacy and safety of gefitinib in advanced non-small ceil lung cancer （NSCLC）. Methods Sixty-six patients with NSCLC received gefitinib as second-line treatment. They were randomly divided into 2 groups, and informed consent forms were signed before grouping. Gefitinib was administrated to the control group, and autologous CIK treatment was added to the observation group. The objective treatment and adverse reactions were evaluated in both groups. Results The objective response rate （ORR） and the disease control rate （DCR） of the observation group were slightly higher than those of the control group, although no statistical differences were found between the 2 groups （P 〉 0.05）. The incidences of diarrhea, fatigue, anorexia, oral ulcers, and myelosuppression in the observation group were much lower than those in the control group （P 〈 0.05）. However, there were no statistical differences between the incidences of skin rash, and liver and kidney toxicities （P 〉 0.05）. Conclusion Autologous CIK in combination with gefitinib is effective as second-line treatment fore ad- vanced NSCLC, and can significantly reduce adverse reactions and improve the objective efficacy.
基金the Natural Sciences Foundation of Anhui Province (No. 2002kj220)
文摘Objective: To detect the expression of CEA mRNA in patients with non-small cell lung cancer (NSCLC) and to investigate it's significance. Methods: The blood samples were taken from peripheral veins of 70 patients with NSCLC and 18 patients with benign diseases at 3 intervals during the surgery. The transcription of carcinoembryonic antigen messenger ribonucleic acid (CEA mRNA) was assayed by means of nested reverse transcriptase polymerase chain reaction (RT-PCR) and micro-fluid chip. Results: The CEA mRNA positive rates at each of the 3 time spots were as follows: 50% at beginning of the surgery (group 1), 62.8% in the samples collected when ligating the pulmonary vein (group 2) and 57.1% in samples collected 1 h after ligation (group 3). A significant difference was found between groups 1 and 2 (χ2 = 7.114, P < 0.05). Con-clusion: Cancer cell dissemination during surgery is demonstrated indirectly in our study, when to ligate the pulmonary vein (earlier or later) may affect the quantity of tumor cells spread into the circulation.
文摘Objective:To study the correlation of peripheral blood NK cell content with tumor marker content and proliferation molecule expression in patients with non-small cell lung cancer (NSCLC).Methods: A total of 80 patients who were diagnosed with NSCLC in our hospital between June 2014 and October 2016 were selected as the NSCLC group of the research, and 96 healthy volunteers who received physical examination in our hospital during the same period were selected as the control group of the research. The peripheral blood NK cell content and serum tumor marker contents of two groups of subjects were determined, and the proliferation molecule expression levels in lung cancer focus tissue and focus tissue adjacent to carcinoma of NSCLC group were determined.Results:Peripheral blood NK cell content of NSCLC group was significantly lower than that of control group;serum CEA, CA125, Cyfra21-1 and HE4 contents were significantly higher than those of control group, and serum CEA, CA125, Cyfra21-1 and HE4 contents of NSCLC patients with high NK cell content were significantly lower than those of NSCLC patients with low NK cell content;c-myc, c-FLIP, Livin, Moesin and k-ras protein expression in lung cancer focus tissue were significantly higher than those in focus tissue adjacent to carcinoma, and c-myc, c-FLIP, Livin, Moesin and k-ras protein expression in lung cancer focus tissue with high NK cell content were significantly lower than those in lung cancer focus tissue with low NK cell content.Conclusion: Peripheral blood NK cell content significantly reduces in patients with NSCLC and is associated with the cancer cell proliferation activity.
文摘Background: Lung cancer is among the most common cancers. Search is ongoing to find biomarkers to improve the diagnosis lung cancer techniques in early stages. In this study we evaluate the sensitivity and specificity of the MUC1 and CEA gene expressions in the peripheral blood of non-small cell lung cancer (NSCLC). Material and Methods: This study was done in Masih Daneshvari Hospital, Tehran, Iran and was case/control study that conducted on 30 NSCLC patients and 30 healthy controls. Peripheral blood was collected and total RNA was extracted then cDNA was synthesized. Sample was separately assessed by real time PCR. Results: The expression of CEA gen was positive in 24 patients indicating 80% sensitivity for this marker. The expression of CEA gen was positive in 9 controls out of 30 each. A statistically significant difference was detected between patients and healthy controls with regard to CEA mRNA expression (P 0.001). The MUC1 gen expressed in 20 out of 30 patients, while it expressed in 3 controls. The difference in MUC1 mRNA expression was statistically significant between NSCLC patients and healthy controls (P 0.001). Conclusion: MUC1 and CEA are molecular biomarkers with relatively favorable sensitivity for primary diagnosis of NSCLC.
文摘目的观察非小细胞肺癌患者癌胚抗原(CEA)、血清细胞角蛋白19片段(CYFRA21-1)、糖类抗原125(CA125)水平在治疗前后的变化,探讨3项肿瘤标志物在评价非小细胞肺癌患者近期疗效和预后中的应用价值。方法选取80例晚期(Ⅲ期、Ⅳ期)非小细胞肺癌患者,均接受至少2个周期的顺铂+吉西他滨(GP)方案或紫杉醇+顺铂(PC)方案化疗。所有患者在化疗前后均检测其血清CEA、CYFRA21-1、CA125水平。结果腺癌患者CEA及CA125水平比鳞癌更高,而鳞癌CYFRA21-1水平比腺癌更高(P<0.05);Ⅳ期、外转移部位数量≥3的患者的CEA、CYFRA21-1、CA125水平均比Ⅲ期、外转移部位数量<3的患者高(P<0.05)。PR患者治疗后血清CEA、CYFRA21-1、CA125水平均比治疗前显著降低(P<0.05)。SD患者治疗前后3项肿瘤标志物水平差异不明显(P>0.05)。PD患者治疗后血清CEA、CYFRA21-1、CA125水平均显著增加(P<0.05)。CEA<15 ng/m L患者的平均PFS、OS均比CEA≥15 ng/m L的患者长(8.48±3.24 VS 5.04±2.03;17.11±5.13 VS 13.11±4.12);CYFRA21-1<5 ng/m L患者的平均PFS、OS均比CYFRA21-1≥5 ng/m L的患者长(8.92±3.47 VS 4.88±2.31;18.01±5.80 VS 13.44±4.75);CA125<30 U/m L患者的平均PFS、OS均比CA125≥30 U/m L的患者长(7.96±3.51 VS 5.91±2.75;16.47±6.52 VS 13.51±5.18),差异均有统计学意义(P<0.05)。结论血清CEA、CYFRA21-1、CA125水平对肿瘤分期及病理分型具有一定的参考意义,在评价晚期非小细胞肺癌患者的近期疗效和预后水平中具有较好的应用价值。
